Proportion of Incident Human Immunodeficiency Virus Cases Among Men Who Have Sex With Men Attributable to Gonorrhea and Chlamydia: A Modeling Analysis.


Journal

Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941

Informations de publication

Date de publication:
06 2019
Historique:
entrez: 17 5 2019
pubmed: 17 5 2019
medline: 7 5 2020
Statut: ppublish

Résumé

Sexually transmitted infections (STIs) are associated with an increased risk of human immunodeficiency virus (HIV) acquisition and transmission. We estimated the proportion of HIV incidence among men who have sex with men attributable to infection with the 2 most common bacterial STIs, Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT). We used a stochastic, agent-based model of a sexual network of MSM with cocirculating HIV, NG, and CT infections. Relative risk (RR) multipliers, specific to anatomic site of infection, modified the risk of HIV transmission and acquisition based on STI status. We estimated the effect of NG and CT on HIV incidence overall and on HIV acquisition and HIV transmission separately. Each scenario was simulated for 10 years. The population attributable fraction (PAF) was determined for each combination of RRs by comparing the incidence in the final year of a scenario to a scenario in which the RRs associated with NG and CT were set to 1.0. Overall, 10.2% (interquartile range [IQR], 7.9-12.4) of HIV infections were attributable to NG/CT infection. Then in sensitivity analyses, the PAF for HIV transmission ranged from 3.1% (IQR, 0.5-5.2) to 20.4% (IQR, 17.8-22.5) and the PAF for HIV acquisition ranged from 2.0% (IQR, -0.7 to 4.3) to 13.8% (IQR, 11.7-16.0). Despite challenges in estimating the causal impact of NG/CT on HIV risk, modeling is an alternative approach to quantifying plausible ranges of effects given uncertainty in the biological cofactors. Our estimates represent idealized public health interventions in which STI could be maximally prevented, setting targets for real-world STI interventions that seek to reduce HIV incidence.

Sections du résumé

BACKGROUND
Sexually transmitted infections (STIs) are associated with an increased risk of human immunodeficiency virus (HIV) acquisition and transmission. We estimated the proportion of HIV incidence among men who have sex with men attributable to infection with the 2 most common bacterial STIs, Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT).
METHODS
We used a stochastic, agent-based model of a sexual network of MSM with cocirculating HIV, NG, and CT infections. Relative risk (RR) multipliers, specific to anatomic site of infection, modified the risk of HIV transmission and acquisition based on STI status. We estimated the effect of NG and CT on HIV incidence overall and on HIV acquisition and HIV transmission separately. Each scenario was simulated for 10 years. The population attributable fraction (PAF) was determined for each combination of RRs by comparing the incidence in the final year of a scenario to a scenario in which the RRs associated with NG and CT were set to 1.0.
RESULTS
Overall, 10.2% (interquartile range [IQR], 7.9-12.4) of HIV infections were attributable to NG/CT infection. Then in sensitivity analyses, the PAF for HIV transmission ranged from 3.1% (IQR, 0.5-5.2) to 20.4% (IQR, 17.8-22.5) and the PAF for HIV acquisition ranged from 2.0% (IQR, -0.7 to 4.3) to 13.8% (IQR, 11.7-16.0).
CONCLUSIONS
Despite challenges in estimating the causal impact of NG/CT on HIV risk, modeling is an alternative approach to quantifying plausible ranges of effects given uncertainty in the biological cofactors. Our estimates represent idealized public health interventions in which STI could be maximally prevented, setting targets for real-world STI interventions that seek to reduce HIV incidence.

Identifiants

pubmed: 31095100
doi: 10.1097/OLQ.0000000000000980
pii: 00007435-201906000-00001
pmc: PMC6530490
mid: NIHMS1519021
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

357-363

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI138783
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCHHSTP CDC HHS
ID : U38 PS004646
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH112449
Pays : United States

Références

Lancet. 2008 Jun 21;371(9630):2109-19
pubmed: 18572080
JMIR Public Health Surveill. 2016 May 17;2(1):e22
pubmed: 27244769
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):567-75
pubmed: 25950207
Sex Transm Dis. 2009 Jun;36(6):365-7
pubmed: 19434009
Sex Transm Infect. 1999 Aug;75(4):261-3
pubmed: 10615314
J Stat Softw. 2018 Apr;84:
pubmed: 29731699
Lancet. 1997 Jun 28;349(9069):1868-73
pubmed: 9217758
N Engl J Med. 2010 Feb 4;362(5):427-39
pubmed: 20089951
J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81
pubmed: 11511825
AIDS Res Hum Retroviruses. 2015 Jun;31(6):587-92
pubmed: 25719950
J Infect Dis. 1995 Dec;172(6):1469-74
pubmed: 7594704
Sex Transm Dis. 2015 Sep;42(9):505-12
pubmed: 26267877
Sex Transm Dis. 2008 Nov;35(11):946-59
pubmed: 18685546
Sex Transm Dis. 2017 Jul;44(7):393-397
pubmed: 28608788
Sex Transm Dis. 2006 Sep;33(9):536-44
pubmed: 16778738
Cochrane Database Syst Rev. 2011 Jun 15;(6):CD007496
pubmed: 21678366
Lancet. 1995 Aug 26;346(8974):530-6
pubmed: 7658778
Int J STD AIDS. 2010 Mar;21(3):207-8
pubmed: 20215629
Ann Epidemiol. 2015 Jun;25(6):445-54
pubmed: 25911980
PLoS One. 2012;7(11):e50522
pubmed: 23209768
Int J Epidemiol. 2017 Oct 1;46(5):1593-1606
pubmed: 28402442
AIDS. 2006 Mar 21;20(5):731-9
pubmed: 16514304
Sex Transm Infect. 2007 Oct;83(6):458-62
pubmed: 17855487
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):337-44
pubmed: 25469526
Clin Infect Dis. 2017 Sep 1;65(5):712-718
pubmed: 28505240
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):537-43
pubmed: 19935075
Lancet. 2000 Jun 3;355(9219):1981-7
pubmed: 10859054
Int J STD AIDS. 2017 Sep;28(10):1034-1037
pubmed: 28081680
Lancet. 2008 Jul 26;372(9635):314-20
pubmed: 18657710
Sex Transm Infect. 1999 Feb;75(1):3-17
pubmed: 10448335

Auteurs

Jonathan Mermin (J)

Centers for Disease Control and Prevention, Atlanta, GA.

Patricia Dietz (P)

Centers for Disease Control and Prevention, Atlanta, GA.

Eli S Rosenberg (ES)

Department of Epidemiology and Biostatistics, University at Albany, Albany, NY.

Thomas L Gift (TL)

Centers for Disease Control and Prevention, Atlanta, GA.

Harrell Chesson (H)

Centers for Disease Control and Prevention, Atlanta, GA.

Cynthia Lyles (C)

Centers for Disease Control and Prevention, Atlanta, GA.

Kyle T Bernstein (KT)

Centers for Disease Control and Prevention, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH